Effects of sotagliflozin: A Synthesis of Findings from 10 Studies

  1. Home
  2. Effects of sotagliflozin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of sotagliflozin: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of sotagliflozin: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Sotagliflozin is a dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and SGLT2, which has been shown to have potential benefits in managing diabetes and heart failure. 9 explored the pharmacology, clinical efficacy, and safety of sotagliflozin in heart failure management. 5 found that sotagliflozin has a dose-dependent effect on glycometabolism in patients with type 1 diabetes. , , , demonstrated that sotagliflozin, when added to insulin therapy, improved glycemic control in patients with type 1 diabetes. 1 highlighted the cardioprotective effects of sotagliflozin in a zebrafish model of diabetic heart failure. 6 suggested that sotagliflozin is safe and effective when used in combination with insulin in type 1 diabetes. 3 compared the metabolic, intestinal, and cardiovascular effects of sotagliflozin to empagliflozin in patients with type 2 diabetes. 2 conducted a meta-analysis to update the metabolic effects of sotagliflozin on blood pressure and body weight reduction in individuals with diabetes. 8 investigated the renal safety profile of sotagliflozin in both type 1 and type 2 diabetes patients. 10 reviewed the adverse events and drug-drug interactions associated with SGLT2 inhibitors in patients with heart failure. examined the impact of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease. explored the effects of sotagliflozin on clinical markers associated with cardiorenal protection in type 1 diabetes patients. 7 found that sotagliflozin attenuated cardiac dysfunction and remodeling in a rat model of myocardial infarction. 4 showed that sotagliflozin, when combined with intensive insulin therapy, improved glycemic control, PPG, and body weight in young adults with type 1 diabetes and suboptimal glycemic control.

Benefits and Risks

Benefits Summary

Sotagliflozin has been shown to improve glycemic control, reduce body weight, and lower blood pressure in patients with diabetes. 5 , , , , , 4 It also exhibits cardioprotective properties and appears to have minimal impact on renal function. 9 , 1 , 8 , 7

Risk Summary

Potential risks associated with sotagliflozin include dehydration, hypoglycemia, urinary tract infections, and vaginal candidiasis. 9

Comparison Between Studies

Commonalities

Numerous studies have consistently demonstrated that sotagliflozin effectively improves glycemic control and reduces body weight. 5 , , , , , 4

Differences

There are some variations among studies, such as the assessment methods used for evaluating the efficacy and safety of sotagliflozin, and the specific patient populations included. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4

Consistency and Inconsistencies in Results

The effectiveness of sotagliflozin can vary across studies. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4

Real-World Applications and Considerations

While sotagliflozin holds promise for improving blood sugar control and potentially offering cardiovascular protection, it's crucial to remember that it can also lead to dehydration and low blood sugar. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4 Therefore, it's vital to take sotagliflozin as directed by your healthcare provider and to be aware of the potential risks.

Limitations of Current Research

The research on sotagliflozin is still ongoing and more studies are needed to fully understand its long-term effects and safety. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4

Future Research Directions

Further large-scale studies are essential to evaluate the long-term effects and safety profile of sotagliflozin in various patient populations. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4

Conclusion

Sotagliflozin shows potential benefits in improving blood sugar control, reducing body weight, and potentially offering cardiovascular protection, although it can also lead to dehydration and low blood sugar. 9 , 5 , , , , , 1 , 6 , 3 , 2 , 8 , 10 , , , 7 , 4 It's essential to take sotagliflozin as directed by your doctor and be aware of the potential risks. More research is needed to fully understand its long-term effects and safety.

Literature analysis of 10 papers
Positive Content
10
Neutral Content
0
Negative Content
0
Article Type
4
1
0
2
10
3.

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.

Author: PoschMaximilian G, WaltherNiklas, FerranniniEle, PowellDavid R, BanksPhillip, WasonSuman, DahmenRaphael

Improved cardiovascular outcomes
Improved glycemic control

This study compared the effects of sotagliflozin (dual SGLT1/SGLT2 inhibitor) and empagliflozin (selective SGLT2 inhibitor) in patients with type 2 diabetes (T2D) and hypertension. Both drugs had similar effects on glycemic and blood pressure control, cardiovascular biomarkers, and other parameters. However, sotagliflozin, but not empagliflozin, inhibited intestinal SGLT1 after breakfast, suggesting transient SGLT1 inhibition.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.

Author: BodeBruce W, CengizEda, WadwaR Paul, BanksPhillip, DanneThomas, KushnerJake A, McGuireDarren K, PetersAnne L, StrumphPaul, SawhneySangeeta

improved A1C
improved A1C goal attainment
reduced PPG
weight loss
DKA
hypoglycemia

This phase 2 study evaluated the efficacy and safety of sotagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as an add-on therapy to insulin in young adults with type 1 diabetes (T1D) and suboptimal glycemic control. The study found that sotagliflozin plus insulin numerically improved A1C and significantly improved A1C goal attainment, postprandial glucose (PPG), and body weight compared to placebo. Sotagliflozin plus insulin was generally well tolerated without any episodes of diabetic ketoacidosis (DKA).

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Author: BakerClaire, WasonSuman, BanksPhillip, SawhneySangeeta, ChangAnna, DanneThomas, Gesty-PalmerDiane, KushnerJake A, McGuireDarren K, MikellFrank, O'NeillMark, PetersAnne L, StrumphPaul

Glycemic control
Weight loss
DKA
Hypoglycemia

Sotagliflozin 200 mg and 400 mg improved glycaemic control and weight in adults with type 1 diabetes, with low rates of severe hypoglycaemia and diabetic ketoacidosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Author: GargSatish K, HenryRobert R, BanksPhillip, BuseJohn B, DaviesMelanie J, FulcherGregory R, PozzilliPaolo, Gesty-PalmerDiane, LapuertaPablo, SimóRafael, DanneThomas, McGuireDarren K, KushnerJake A, PetersAnne, StrumphPaul

Improved glycemic control
Lower blood pressure
Reduced insulin dose
Weight loss
Diabetic ketoacidosis

Sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, significantly improved glycemic control in patients with type 1 diabetes receiving insulin therapy. However, it was also associated with a higher rate of diabetic ketoacidosis.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats.

Author: ZhongPeng, ZhangJingjing, WeiYanzhao, LiuTao, ChenMinxiao

Cardioprotection

This study aims to investigate the cardioprotective effects of sotagliflozin, a dual SGLT1/2 inhibitor, in an animal model of myocardial infarction (MI).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.

Author: LongAllissa, SalvoMarissa

Heart failure management
Reduced cardiovascular events
Limited evidence
Safety concerns

Sotagliflozin, a dual SGLT1/SGLT2 inhibitor, showed promise in reducing cardiovascular and heart failure events in patients with type 2 diabetes mellitus. However, compared to other SGLT2 inhibitors, sotagliflozin has limited evidence and requires further investigation to determine its benefit.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure.

Author: StöllbergerClaudia, FinstererJosef, SchneiderBirke

Drug-drug interactions

This review summarizes the adverse events (AE) and drug-drug interactions (DDI) of dapagliflozin, empagliflozin, and sotagliflozin, sodium glucose co-transporter 2-inhibitors (SGLT2-I) used in chronic heart failure (CHF).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.